(426) clinical follow-UP of patients with multiple sclerosis 10 years after PDE5IS treatment for erectile dysfunction: a real-life cohort study
Abstract
Erectile Dysfunction (ED) is very common in patients suffering from Multiple Sclerosis (MS); the prevalence varies from 30% to almost 90%.Our aim was to study the adherence of MS patients to PDE5Is, in 10 years period.
119 MS patients suffering from ED that were treated with PDE5Is were evaluated in 2015. Concomitant cardiovascular diseases, hormonal and psychiatric disorders were excluded. Efficacy was evaluated with IIEF5 and SEP2&3 questions.
We re-evaluate our data now in order to assess the adherence to PDE5Is, almost 10 years after.
10 years after we collected data from 94 patients out of the original 101 responders.
From the sildenafil group, 20 out of 36 are still on, 5 on daily tadalafil, 1 on intra-cavernosal injections (ICI), 1 died, 3 were lost from follow up, 1 underwent a 3-piece inflatable penile prosthesis insertion, 2 stopped due to lack of sexual partner and 3 stopped due to MS progression.
From the vardenafil group, 5/15 are still on, 2 on sildenafil, 2 on daily tadalafil, 1 on ICC, 3 without partner and 2 stopped due to progression.
From the avanafil group, 4/8 responders are still on, 1 ion sildenafil, 1 on daily tadalafil, 1 on ICC and 1 stopped to progression.
From the on demand tadalafil group, 7/18 are still on, 5 on daily tadalafil, 1 on sildenafil, 2 were lost from follow up, 1 on ICC, 1 without partner and 1 stopped due to progression.
From daily tadalafil group, 10/24 are still on, 1 is dead, 1 on ICC, 6 on sildenafil on, 1 underwent penile…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 119 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.